MedTrace Logo

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

NCT04517305 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2021-06-18

No results posted yet for this study

Summary

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Biyun Wang, Professor · Fudan University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2021-05-15
Completion
2021-05-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517305 on ClinicalTrials.gov